Dianthus Therapeutics, Inc. (NASDAQ: DNTH) is a Healthcare company (Biotechnology) with a market capitalization of $4.9B. The Maz Rating grades it against the other companies in its sector.
Dianthus Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $86.98, Dianthus Therapeutics, Inc. trades at 2898.5x trailing earnings, 1801.6x sales and 4.0x book value. Over the last twelve months it generated about $3M of revenue and $2M of net income. It runs a gross margin of 97.2%, an operating margin of -8683.9% and a net margin of -1463.8%. It shows return on equity of -3.9%, return on invested capital of -18.9% and a free cash flow yield of -3.6%. On the balance sheet: a debt-to-equity ratio of 0.00 and a current ratio of 30.02. Over the past 52 weeks the share price ranged from $35.84 to $117.88, with a beta of 0.08.
Dianthus Therapeutics, Inc. does not currently pay a dividend.
11 Wall Street analyst ratings cover the stock: 1 Strong Buy and 10 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.